HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD.

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

301096

CNE1000056N5

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
63.48 ^CNY	-2.88%		-5.90%	-2.49%

Apr. 22	Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
2023	Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.	CI

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.(XSEC:301096) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 22	CI
Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.	Dec. 21	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback announced on August 24, 2023, has closed with 777,300 shares, representing 0.72% for CNY 49.99 million,	Dec. 19	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-25	CI
Tranche Update on Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.'s Equity Buyback Plan announced on August 24, 2023.	23-10-10	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.(XSEC:301096) added to S&P Global BMI Index	23-09-18	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. announces an Equity Buyback for CNY 50 million worth of its shares.	23-08-24	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. authorizes a Buyback Plan.	23-08-23	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-09	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Approves Cash Dividend for 2022, Payable on 04 May 2023	23-04-20	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Proposes Cash Dividend for the Year 2022	23-03-28	CI
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-12	CI

Chart Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

Duration

Period

Chart Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

More charts

Hangzhou Bio-Sincerity Pharma-Tech Co Ltd is a China-based company mainly engaged in comprehensive pharmaceutical technology research and development (R&D). The services provided by the Company mainly include entrusted R&D of pharmaceutical technology and transformation of independent R&D technological achievements. The entrusted R&D business provides integrated pharmaceutical R&D services such as pharmaceutical research, clinical trial and registration application for major pharmaceutical enterprises and pharmaceutical R&D investment enterprises. The transformation business of independent R&D technological achievements is based on the independent project research and development of drug R&D platform, and actively promote the transformation of independent R&D technological achievements after obtaining phased R&D achievements.

Sector

Biotechnology & Medical Research

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

63.48

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HANGZHOU BIO-SINCERITY PHARMA-TECH CO.,LTD.	-2.49%	951M
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research